You're signed outSign in or to get full access.
Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP is a US-based investment adviser headquartered in New York, NY. The firm focuses on investments in the biotechnology and life sciences sectors, managing public and private investments. Founded in the early 2020s, Paradigm Biocapital Advisors employs around 9 professionals, serving institutional and high-net-worth clients with interests in biomedical innovation and healthcare advancement.
Investment Strategy
Paradigm Biocapital Advisors LP employs a sector-focused strategy, primarily investing in biotechnology and life sciences companies. The firm utilizes in-depth scientific and industry research to identify undervalued public and, on occasion, private opportunities, often taking concentrated positions in companies developing breakthrough therapies and technologies. Their approach emphasizes fundamental analysis, engagement with company management, and active monitoring to optimize long-term value creation.
Latest 13F Filing Activity
Paradigm Biocapital Advisors LP filed their most recent 13F report on Jun 30, 2025 disclosing 27 equity positions with a total 13F market value of $2B. The fund increased holdings in Merus N V, Scholar Rock HLDG Corp., Vaxcyte Inc. among other positions. Paradigm Biocapital Advisors LP reduced exposure to Argenx SE, Cytokinetics Inc., Insmed Inc. among others.
Top Holdings
Equity Positions (27)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
N NUVL | NUVALENT INC | 17.17% | $402.1M | 5,269,433 | $67.32 | $76.30 | +$28.3M |
A ACLX | ARCELLX INC | 13.07% | $306.1M | 4,649,016 | $44.21 | $65.85 | +$11.5M |
M MRUS | MERUS N V | 9.62% | $225.2M | 4,281,954 | $48.89 | $52.60 | +$83.4M |
R RVMD | REVOLUTION MEDICINES INC | 9.57% | $224.2M | 6,093,291 | $36.63 | $36.79 | +$5.7M |
T TARS | TARSUS PHARMACEUTICALS INC | 5.15% | $120.6M | 2,976,099 | $32.86 | $40.51 | -$13.5M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more